Literature DB >> 2055424

Buprenorphine: bell-shaped dose-response curve for its antagonist effects.

I Lizasoain1, J C Leza, P Lorenzo.   

Abstract

1. Doses of buprenorphine (0.01, 0.1, 0.5, 1, 5, 10 and 50 mg/kg) were administered to determine buprenorphine's ability to precipitate abstinence symptoms in morphine-dependent mice. 2. When buprenorphine was administered in the fourth day of morphine addiction, the results demonstrate that the administration of the partial agonist opioid produce a bell-shaped dose-response curve. 3. The highest dose (50 mg/kg) was partially inactive while lower doses causing similar percentage than group treated with naloxone with respect to the appearance of the most of the symptoms of abstinence studied (diarrhoea, tremor, shaking-"wet dog shakes"-, jumping and weight loss). 4. Our findings demonstrate the bell-shaped response curve of the antagonist effects of buprenorphine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2055424     DOI: 10.1016/0306-3623(91)90452-c

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  12 in total

1.  Oligodendrocyte responses to buprenorphine uncover novel and opposing roles of μ-opioid- and nociceptin/orphanin FQ receptors in cell development: implications for drug addiction treatment during pregnancy.

Authors:  Andrew C Eschenroeder; Allison A Vestal-Laborde; Emilse S Sanchez; Susan E Robinson; Carmen Sato-Bigbee
Journal:  Glia       Date:  2011-10-14       Impact factor: 7.452

Review 2.  The switch from buprenorphine to tapentadol: is it worth?

Authors:  Adriana Miclescu
Journal:  Rom J Anaesth Intensive Care       Date:  2016-10

3.  Buprenorphine: a unique drug with complex pharmacology.

Authors:  Kabirullah Lutfy; Alan Cowan
Journal:  Curr Neuropharmacol       Date:  2004-10       Impact factor: 7.363

4.  Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system.

Authors:  Roberto Ciccocioppo; Daina Economidou; Roberto Rimondini; Wolfgang Sommer; Maurizio Massi; Markus Heilig
Journal:  Biol Psychiatry       Date:  2006-03-14       Impact factor: 13.382

5.  Clinical efficacy of buprenorphine to minimize distress in MRL/lpr mice.

Authors:  Julie Swenson; Selen Olgun; Ali Radjavi; Taranjit Kaur; Christopher M Reilly
Journal:  Eur J Pharmacol       Date:  2007-04-06       Impact factor: 4.432

6.  Buprederm, a new transdermal delivery system of buprenorphine: pharmacokinetic, efficacy and skin irritancy studies.

Authors:  In Park; Dongwon Kim; Jindeog Song; Chang Hoon In; Seung-Wei Jeong; Sang Hun Lee; Bumchan Min; Dongho Lee; Sun-Ok Kim
Journal:  Pharm Res       Date:  2008-02-01       Impact factor: 4.200

Review 7.  Endogenous and exogenous opioid effects on oligodendrocyte biology and developmental brain myelination.

Authors:  Brandon Velasco; Esraa Mohamed; Carmen Sato-Bigbee
Journal:  Neurotoxicol Teratol       Date:  2021-06-12       Impact factor: 4.071

Review 8.  Systematic Review of Pharmacological Properties of the Oligodendrocyte Lineage.

Authors:  Carla Marinelli; Thomas Bertalot; Morena Zusso; Stephen D Skaper; Pietro Giusti
Journal:  Front Cell Neurosci       Date:  2016-02-12       Impact factor: 5.505

9.  Comparison of spinal block after intrathecal clonidine-bupivacaine, buprenorphine-bupivacaine and bupivacaine alone in lower limb surgeries.

Authors:  Major Vishal Arora; Mohammad Zafeer Khan; Major Sanjay Choubey; Mohammad Asim Rasheed; Arindam Sarkar
Journal:  Anesth Essays Res       Date:  2016 Sep-Dec

Review 10.  A review of the studies using buprenorphine in cats.

Authors:  P V M Steagall; B P Monteiro-Steagall; P M Taylor
Journal:  J Vet Intern Med       Date:  2014-03-21       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.